Table 3 Potential confounders stratified by donepezil use
| Â | Donepezil (\(n=134\)) | Control (\(n=483\)) | SMD\(^a\) |
|---|---|---|---|
Cardiovascular Issues - Yes (n (%))\(^{c}\) | 96 (71.6) | 342 (70.8) | 0.018 |
Neurological Issues - Yes (n (%))\(^{c}\) | 43 (32.1) | 171 (35.4) | 0.070 |
Renal Issues - Yes (n (%))\(^{c}\) | 67 (50.0) | 210 (43.5) | 0.131 |
Age (mean (SD)) | 74.92 (6.69) | 72.96 (7.71) | 0.271 |
Sex - Male (n (%)) | 81 (60.4) | 282 (58.4) | 0.042 |
Years Education (mean (SD)) | 15.81 (2.65) | 16.23 (2.67) | 0.158 |
APOE4 Count (n (%)) | Â | Â | 0.306 |
  0 | 60 (44.8) | 283 (58.6) |  |
  1 | 56 (41.8) | 166 (34.4) |  |
  2 | 18 (13.4) | 34 (7.0) |  |
Time in ADNI (mean (SD)) | 1.19 (2.03) | 0.41 (1.50) | 0.437 |
A\(\beta\) (mean (SD))\(^{b,c}\) | 781.21 (354.35) | 1096.50 (441.29) | 0.788 |
P-tau (mean (SD))\(^{b,c}\) | 29.61 (12.61) | 26.17 (12.63) | 0.272 |
Starting ADAS-cog (mean (SD))\(^{c}\) | 11.90 (4.46) | 8.88 (3.96) | 0.714 |